Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
This article was originally published in The Pink Sheet Daily
Executive Summary
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.